StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE – Free Report) in a research note published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.
Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company cut their target price on bluebird bio from $3.00 to $2.00 and set an equal weight rating for the company in a research note on Wednesday, September 25th. JPMorgan Chase & Co. cut bluebird bio from an overweight rating to a neutral rating in a report on Thursday, August 15th. Bank of America reduced their price objective on bluebird bio from $4.00 to $3.00 and set a buy rating on the stock in a research note on Thursday, August 15th. Cantor Fitzgerald reissued a neutral rating on shares of bluebird bio in a research note on Monday, September 16th. Finally, Barclays reduced their price target on shares of bluebird bio from $8.00 to $4.00 and set an overweight rating on the stock in a research note on Thursday, August 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of Hold and an average target price of $4.63.
View Our Latest Stock Report on bluebird bio
bluebird bio Price Performance
Hedge Funds Weigh In On bluebird bio
Several large investors have recently modified their holdings of the business. Ghisallo Capital Management LLC acquired a new stake in bluebird bio in the fourth quarter valued at $4,347,000. Pennant Investors LP acquired a new stake in shares of bluebird bio in the fourth quarter valued at about $121,000. Masters Capital Management LLC bought a new position in shares of bluebird bio during the fourth quarter worth about $1,380,000. Virtu Financial LLC acquired a new position in shares of bluebird bio in the fourth quarter worth approximately $317,000. Finally, HBK Investments L P bought a new stake in bluebird bio in the fourth quarter valued at approximately $2,070,000. Institutional investors own 87.43% of the company’s stock.
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Featured Articles
- Five stocks we like better than bluebird bio
- The 3 Best Blue-Chip Stocks to Buy Now
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Earnings Per Share Calculator: How to Calculate EPS
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Stock Market Upgrades: What Are They?
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.